Suppr超能文献

CpG诱导的先天免疫防御不能促进猪对口蹄疫病毒疫苗诱导的保护。

Innate immune defenses induced by CpG do not promote vaccine-induced protection against foot-and-mouth disease virus in pigs.

作者信息

Alves M P, Guzylack-Piriou L, Juillard V, Audonnet J-C, Doel T, Dawson H, Golde W T, Gerber H, Peduto N, McCullough K C, Summerfield A

机构信息

Institute of Virology and Immunoprophylaxis, Mittelhäusern, Switzerland.

出版信息

Clin Vaccine Immunol. 2009 Aug;16(8):1151-7. doi: 10.1128/CVI.00018-09. Epub 2009 Jun 24.

Abstract

Emergency vaccination as part of the control strategies against foot-and-mouth disease virus (FMDV) has the potential to limit virus spread and reduce large-scale culling. To reduce the time between vaccination and the onset of immunity, immunostimulatory CpG was tested for its capacity to promote early protection against FMDV challenge in pigs. To this end, CpG 2142, an efficient inducer of alpha interferon, was injected intramuscularly. Increased transcription of Mx1, OAS, and IRF-7 was identified as a sensitive measurement of CpG-induced innate immunity, with increased levels detectable to at least 4 days after injection of CpG formulated with Emulsigen. Despite this, CpG combined with an FMD vaccine did not promote protection. Pigs vaccinated 2 days before challenge had disease development, which was at least as acute as that of unvaccinated controls. All pigs vaccinated 7 days before challenge were protected without a noticeable effect of CpG. In summary, our results demonstrate the caution required when translating findings from mouse models to natural hosts of FMDV.

摘要

紧急接种疫苗作为口蹄疫病毒(FMDV)防控策略的一部分,有潜力限制病毒传播并减少大规模扑杀。为缩短接种疫苗与产生免疫力之间的时间,对免疫刺激型CpG促进猪早期抵御FMDV攻击的能力进行了测试。为此,肌肉注射了α干扰素的高效诱导剂CpG 2142。Mx1、OAS和IRF-7转录增加被确定为CpG诱导先天免疫的敏感指标,注射与Emulsigen配制的CpG后,至少4天内均可检测到其水平升高。尽管如此,CpG与FMD疫苗联合使用并未促进保护作用。在攻击前2天接种疫苗的猪出现了疾病发展,其严重程度至少与未接种疫苗的对照组一样严重。所有在攻击前7天接种疫苗的猪都受到了保护,CpG没有明显影响。总之,我们的结果表明,将小鼠模型的研究结果转化到FMDV的自然宿主时需要谨慎。

相似文献

1
Innate immune defenses induced by CpG do not promote vaccine-induced protection against foot-and-mouth disease virus in pigs.
Clin Vaccine Immunol. 2009 Aug;16(8):1151-7. doi: 10.1128/CVI.00018-09. Epub 2009 Jun 24.
6
Rational design and efficacy of a multi-epitope recombinant protein vaccine against foot-and-mouth disease virus serotype A in pigs.
Antiviral Res. 2017 Apr;140:133-141. doi: 10.1016/j.antiviral.2017.01.023. Epub 2017 Feb 1.
7
Coinjection of a vaccine and anti-viral agents can provide fast-acting protection from foot-and-mouth disease.
Antiviral Res. 2017 Jul;143:195-204. doi: 10.1016/j.antiviral.2017.04.009. Epub 2017 Apr 25.
8
Poly(I:C) combined with multi-epitope protein vaccine completely protects against virulent foot-and-mouth disease virus challenge in pigs.
Antiviral Res. 2013 Feb;97(2):145-53. doi: 10.1016/j.antiviral.2012.11.009. Epub 2012 Dec 7.

引用本文的文献

1
Preliminary evaluation of a novel serotype O foot-and-mouth disease mRNA vaccine.
Front Microbiol. 2025 Apr 28;16:1503191. doi: 10.3389/fmicb.2025.1503191. eCollection 2025.
3
Enhanced Effects of ISA 207 Adjuvant via Intradermal Route in Foot-and-Mouth Disease Vaccine for Pigs.
Vaccines (Basel). 2024 Aug 26;12(9):963. doi: 10.3390/vaccines12090963.
4
Isoprinosine as a foot-and-mouth disease vaccine adjuvant elicits robust host defense against viral infection through immunomodulation.
Front Cell Infect Microbiol. 2024 Mar 6;14:1331779. doi: 10.3389/fcimb.2024.1331779. eCollection 2024.
7
Dectin-1 signaling coordinates innate and adaptive immunity for potent host defense against viral infection.
Front Immunol. 2023 Jun 2;14:1194502. doi: 10.3389/fimmu.2023.1194502. eCollection 2023.

本文引用的文献

1
Toll-like receptor 7 and MyD88 knockdown by lentivirus-mediated RNA interference to porcine dendritic cell subsets.
Gene Ther. 2007 May;14(10):836-44. doi: 10.1038/sj.gt.3302930. Epub 2007 Mar 1.
2
Silencing of natural interferon producing cell activation by porcine circovirus type 2 DNA.
Immunology. 2007 Jan;120(1):47-56. doi: 10.1111/j.1365-2567.2006.02476.x. Epub 2006 Oct 13.
3
Protection of Balb/c mice against infection with FMDV by immunostimulation with CpG oligonucleotides.
Antiviral Res. 2006 Oct;72(1):42-8. doi: 10.1016/j.antiviral.2006.03.010. Epub 2006 Apr 18.
4
Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha.
Vaccine. 2006 Apr 24;24(17):3446-56. doi: 10.1016/j.vaccine.2006.02.011. Epub 2006 Feb 20.
5
Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.
Biologicals. 2005 Dec;33(4):227-34. doi: 10.1016/j.biologicals.2005.08.009. Epub 2005 Nov 14.
6
Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.
Expert Opin Biol Ther. 2005 May;5(5):673-82. doi: 10.1517/14712598.5.5.673.
7
Targeting the innate immune response with improved vaccine adjuvants.
Nat Med. 2005 Apr;11(4 Suppl):S63-8. doi: 10.1038/nm1210.
8
CpG-DNA protects against a lethal orthopoxvirus infection in a murine model.
Antiviral Res. 2005 Feb;65(2):87-95. doi: 10.1016/j.antiviral.2004.10.004.
9
Natural and vaccine induced immunity to FMD.
Curr Top Microbiol Immunol. 2005;288:103-31. doi: 10.1007/3-540-27109-0_5.
10
Foot-and-mouth disease: host range and pathogenesis.
Curr Top Microbiol Immunol. 2005;288:9-42. doi: 10.1007/3-540-27109-0_2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验